Last reviewed · How we verify
Feraheme
At a glance
| Generic name | Feraheme |
|---|---|
| Also known as | IV iron, Ferumoxytol, ferumoxytol, Ferumoxytole, ferumoxytol, iron |
| Sponsor | University of Texas Southwestern Medical Center |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- Iron deficiency anemia
Common side effects
- Headache
- Nausea
- Dizziness
- Fatigue
- Diarrhea
- Back Pain
Serious adverse events
- Syncope
- Gastroenteritis
- Seizure
- Pneumonia
- Hemorrhagic Anemia
- Acute Kidney Injury
Key clinical trials
- In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging (PHASE1)
- Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous Diseases (PHASE2)
- Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients (PHASE3)
- Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System (PHASE2)
- Effectiveness of Topical Magnetite Zinc Oxide Composite Nanoparticles in the Management of Oral Potentially Malignant Lesions (EARLY_PHASE1)
- A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |